Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. All rights reserved. Fujifilm Expands its Advanced Therapies CDMO Business with Alex Chapman 805-456-4772 2023 Atara Biotherapeutics, Inc. All rights An archived replay will be available on the Company's website for 30 days. +1 805 699 5579, 300 N. Beacon Street, For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) . Atara will retain its expertise, staff, and capabilities in manufacturing process science to continue to innovate in initial manufacturing and scale up for allogeneic cell therapies. As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Ataras promising clinical and commercial-stage allogeneic cell therapies at the site, including tabelecleucel (tab-cel), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress. Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. A live audio webcast can be accessed by visiting the Investors & Media News & Events section of www.atarabio.com. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras sale of its manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the supply agreement and meet Ataras requirements, FDBs plans for the manufacturing facility, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. christine.jackman@fujifilm.com Pipeline, Stories of Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Atara Biotherapeutics, Inc.: , , Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. Eric Hyllengren A live audio webcast can be accessed by visiting the Investors & Media News & Events section of www.atarabio.com. Global Multicancer Screening Market to Reach $7.78 Billion by 2032 Atara expects to report cash, cash equivalents and short-term investments of $371.1 million as of December 31, 2021. FUJIFILM Holdings America Corporation. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. Healthcare Providers, https://www.businesswire.com/news/home/20220126006000/en/. FUJIFILM Diosynth Biotechnologies California, Inc. completed the Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. Investors Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). 805-395-9669 We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. Leading Global rewards project planning and execution. Access. This partnership and acquisition was first announced in January 2022. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. For more information, please visit: https://www.fujifilmholdings.com. We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). 04:05PM. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. THOUSAND OAKS, Calif., December 20, 2022 -- ( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. HCRx is a leading royalty acquisition company focused on commercial or near . SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with Despite also reporting a financial loss for the quarter, Atara's shares climbed nearly 24% Tuesday morning to . Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. The facility is the newest addition to FUJIFILM Diosynth Biotechnologies global portfolio of manufacturing sites which include facilities in College Station, Texas, USA, Research Triangle Park, North Carolina, USA, Teesside, UK, and Hillerd, Denmark. Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. Christine Jackman At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. With the addition of the dedicated site in California, Fujifilm continues to build for the future to meet the growing need of advanced therapies globally., We are excited to welcome 134 new team members to the FUJIFILM Diosynth Biotechnologies family today with the acquisition of the dedicated cell therapy manufacturing facility. Fujifilm Completes Acquisition of a Dedicated Cell Therapy - IMAPAC Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. Moffitt Cancer Center With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. Christine Jackman Cookies are important to the proper functioning of a site. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Healthcare Providers, https://www.businesswire.com/news/home/20220401005459/en/. Atara Biotherapeutics, Inc. . 914-789-8523, Photofinishing & Personalized Photo Products. View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005459/en/, INVESTORS & MEDIA: Investors Strength, Multiple ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. Atara Biotherapeutics Strengthens Board; Senior Management Team Fujifilm Investors With our lead program in Phase 3 clinical development . Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the commercial launch of tab-cel. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. Were the first company ever to receive an approval for an allogeneic T-cell immunotherapy. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. The agreement is expected to reduce Ataras planned operating expenses over the multiyear partnership period. Article Summary FUJIFILM has acquired the facility from Atara Biotherapeutics which is located in Thousand Oaks, California. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. Explore patient stories, our clinical studies, The Engineering MSAT team supports the technical activities associated with T-cell manufacturing across the Atara manufacturing network. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Media We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. About FUJIFILM Corporation Sign up today for your free Reader Account. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Furthermore, in order to expand the business in the most advanced biopharmaceutical fields, FUJIFILM Diosynth Biotechnologies joined Landmark Bio, the industry-academia research and development consortium,to explore the application of genetically modified cell therapies. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. +1 919 337 4400, Belasis Avenue Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. In its pursuit to establish itself as a comprehensive healthcare company covering prevention, treatment and diagnosis, FUJIFILM Corporation has made multiple strategic acquisitions over recent years to expand and diversify its healthcare portfolio. FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in The agreement is expected to reduce Ataras planned operating expenses over the multiyear partnership period. Atara Biotherapeutics Announces the Completion of the Acquisition of achapman@atarabio.com, Atara Alex Chapman Going forward, Fujifilm will, by providing a stable supply of high quality biopharmaceuticals, further advance establishing tomorrows medicines that fulfill unmet medical needs., We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. 2023 Atara Biotherapeutics, Inc. All rights View source version on businesswire.com: https://www.businesswire.com/news/home/20220126006000/en/, INVESTORS & MEDIA:

River Valley Ingredients Cuthbert Georgia, Moon Trine Lilith Synastry, Will And Nico Mpreg Fanfiction, Articles A